Abstract

The prognostic variables for bladder cancer recurrence and survival are few and contradictory at this time. KPNA2 is a member of the karyopherin (importin) family. However, there is presently no relevant study on KPNA2 expression in bladder cancer. The objective of this systematic review and meta-analysis was to investigate the predictive value of KPNA2 in bladder tumor patients.

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
RECURRENCE AND PROGRESSION OF STAGE T1, GRADE 3 TRANSITIONAL CELL CARCINOMA OF THE BLADDER FOLLOWING INTRAVESICAL IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERIN
M Brake ... H Keller
The Journal of Urology | VOL. 163
M Brake, et. al.M Brake ... H Keller
01 Jun 2000
The clinicopathological and prognostic significances of EZH2 expression in urological cancers: A meta‑analysis and bioinformatics analysis.
Yang-Kai Bai ... Qing-Le Xu
Oncology Letters | VOL. 26
Yang-Kai Bai, et. al.Yang-Kai Bai ... Qing-Le Xu
06 Jun 2023
Abstract 3792: Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
Neelam Mukherjee ... Marcela A Flores
Cancer Research | VOL. 78
Neelam Mukherjee, et. al.Neelam Mukherjee ... Marcela A Flores
01 Jul 2018
The Importance of Transurethral Resection of Bladder Tumor in the Management of Nonmuscle Invasive Bladder Cancer: A Systematic Review of Novel Technologies
Kyle A Richards ... Gary D Steinberg
Journal of Urology | VOL. 191
Kyle A Richards, et. al.Kyle A Richards ... Gary D Steinberg
08 Feb 2014
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
T André ... L.A Diaz
Annals of Oncology | VOL. -
T André, et. al.T André ... L.A Diaz
01 Dec 2024
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
J.-Y Blay ... A Le Cesne
Annals of Oncology | VOL. 35
J.-Y Blay, et. al.J.-Y Blay ... A Le Cesne
01 Dec 2024
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
T.M Kim ... S Luminari
Annals of Oncology | VOL. -
T.M Kim, et. al.T.M Kim ... S Luminari
01 Dec 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
A Di Federico ... J Luo
Annals of Oncology | VOL. -
A Di Federico, et. al.A Di Federico ... J Luo
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.